Human glioblastoma in mouse

Publications

The following includes selected recent publications from our lab.

Is the immune response a friend or foe for viral therapy of glioma?

Okada H, Thorne SH.

Neuro Oncol. 2017 Jul 1; 19 (7): 882-883. doi: 10.1093/neuonc/nox082.
PubMed Link >

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H.

J Clin Invest. 2017 Apr 3; 127 (4): 1425-1437. doi: 10.1172/JCI90644. Epub 2017 Mar 20.
PubMed Link >

Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine

Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM.

Sci Rep. 2016 Aug 10; 6: 31397. doi: 10.1038/srep31397.
PubMed Link >

Prioritization schema for immunotherapy clinical trials in glioblastoma

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. 

Oncoimmunology. 2016 Feb 18; 5 (6): e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun.
PubMed Link >

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience

Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A.

Neuroimaging Clin N Am. 2017; 27 (1): 155-166. doi: 10.1016/j.nic.2016.09.002.
PubMed Link >

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. 

J Neurooncol. 2016; 130 (3): 517-527. Epub 2016 Sep 13.
PubMed Link >

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H.

J Neurooncol. 2016; 130 (3): 543-552. Epub 2016 Sep 13.
PubMed Link >

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N.

Neuro Oncol. 2016; 18 (10): 1402-12. doi: 10.1093/neuonc/now061. Epub 2016 Apr 25.
PubMed Link >

Cellular immunotherapy for malignant gliomas

Lin Y, Okada H.

Expert Opin Biol Ther. 2016; 16 (10): 1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29.
PubMed Link >

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H.

Neuro Oncol. 2016; 18 (8): 1157-68. doi: 10.1093/neuonc/now026. Epub 2016 Mar 15.
PubMed Link >